黑色素诱导通过MT2受体介导的神经免疫调节在小鼠前皮质诱导止痛作用
Jian Wang1,2, Junxiang Gu1,3, Fujuan Ma1,4
1Department of Anatomy and K.K. Leung Brain Research Centre, Fourth Military Medical University, Xi'an 710032, China.
Research (Washington, D.C.)
|October 9, 2024
概括
黑素 (MLT) 通过向前带带皮层 (ACC) 中的MT2受体来缓解神经病痛 (NP). 这种神经免疫调节减少了神经元刺激性和炎症,为慢性疼痛提供了新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 神经病痛 (NP) 是一种具有有限治疗选择的衰弱性疾病.
- 黑色素 (MLT),以其促进睡眠的作用而闻名,显示潜在的止痛特性.
- 精确的MLT缓解疼痛效应的机制,特别是在皮质中,尚未完全理解.
研究的目的:
- 调查黑激素在缓解神经病痛方面的疗效和潜在机制.
- 探索前带状皮质 (ACC) 和其特定受体在MLT止痛作用中的作用.
- 在慢性疼痛的背景下,阐明由MLT影响的神经免疫调节途径.
主要方法:
- 使用节省的神经损伤 (SNI) 建立了一个神经病痛小鼠模型.
- 黑色素被输入腹膜内,并直接进入前带带皮层 (ACC).
- 分析了神经病痛症状,受体参与 (MT1R,MT2R),神经元刺激性,微质极化和基因表达.
主要成果:
- 黑素显著缓解了神经病痛症状,以剂量依赖的方式.
- 在ACC中,镇痛效应是由MT2受体 (MT2R) 选择性介导的,而不是MT1R.
- 黑色素调节了Gα (i) 信号以减少金字塔细胞刺激性,并将微质从M1转移到M2表型,减少炎症.
结论:
- 黑色素通过在ACC中MT2R介导的神经免疫调节来减轻神经病痛.
- 这一途径涉及抑制神经元刺激性和促进抗炎微质反应.
- 黑素为治疗慢性神经病痛提供了一个有前途的治疗策略.
相关概念视频
01:25Analgesia and Pain Management
540
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
540
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
149
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
149